Instrument Inactif

Communiqués Acer Therapeutics Inc.

Actions

ACER

US00444P1084

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Acer Therapeutics Shareholders Vote "FOR" the Proposed Merger and Related Proposals	02/11	AQ
ACER THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acer Therapeutics Inc. - ACER	10/10/23	BU
ACER THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acer Therapeutics Inc. - ACER	06/09/23	BU
Shareholder Alert: Ademi LLP investigates whether Acer Therapeutics Inc. has obtained a Fair Price in its transaction with Zevra	31/08/23	PR
ACER Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Acer Therapeutics Inc. Is Fair to Shareholders	31/08/23	BU
Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product	31/08/23	AQ
Acer Therapeutics Reacquires Worldwide Development, Commercialization and Economic Rights to OLPRUVA™ from Relief Therapeutics, Excluding the Geographical Europe	30/08/23	AQ
Acer Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update	14/08/23	AQ
Acer Therapeutics Receives $1 Million Capital Infusion from Chief Executive Officer and Founder	26/06/23	AQ
Acer Therapeutics : Failure to Satisfy Listing Rule - Form 8-K	07/06/23	PU
ACER THERAPEUTICS INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)	15/05/23	AQ
Acer Therapeutics Reports Q1 2023 Financial Results and Provides Corporate Update	15/05/23	AQ
ACER THERAPEUTICS INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	04/05/23	AQ
ACER THERAPEUTICS INC. : Other Events, Financial Statements and Exhibits (form 8-K)	01/05/23	AQ
Acer Therapeutics Announces OLPRUVA™ Commercial Launch Progressing Ahead of Schedule	01/05/23	AQ
Acer Therapeutics : Sales Agreement - Form 8-K	27/04/23	PU
ACER THERAPEUTICS INC. : Other Events, Financial Statements and Exhibits (form 8-K)	27/04/23	AQ
ACER THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	27/03/23	AQ
ACER THERAPEUTICS INC. : Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	27/03/23	AQ
Acer Therapeutics Reports Q4 and Full Year 2022 Financial Results and Provides Corporate Update	27/03/23	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Acer Therapeutics Inc.

Actions

ACER

US00444P1084

Communiqués

Filtres